SCHEMBL6441880

SCHEMBL6441880

N#Cc1c(NCCCc2ccccc2)nc(N)nc1-c1ccc2c(c1)OCO2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 17/20 0.64
ADORA2A P29274 9/20 0.64
ADORA2B P29275 4/20 0.64
MEN1 O00255 2/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
MAPK1 P28482 2/20 0.46
KMT2A Q03164 2/20 0.46
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ADORA3 P0DMS8 1/20 0.43
PIM1 P11309 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441578 0.94 ADORA1 (0.67) ADORA1ADORA2AADORA2BMEN1ALDH1A1
SCHEMBL6446302 0.88 ADORA1 (0.69) ADORA1ADORA2AADORA2BMEN1ALDH1A1
SCHEMBL6441685 0.85 ADORA1 (0.56) ADORA1ADORA2AADORA2BMEN1ALDH1A1
SCHEMBL6442437 0.84 ADORA1 (0.62) ADORA1ADORA2AADORA2BMEN1ALDH1A1
SCHEMBL6443635 0.84 ADORA1 (0.57) ADORA1ADORA2AADORA2BALDH1A1LMNA
SCHEMBL6441934 0.79 ADORA1 (0.55) ADORA1ADORA2AADORA2BMEN1ALDH1A1
SCHEMBL6443028 0.77 ADORA1 (0.60) ADORA1ADORA2AADORA2BALDH1A1GAA
SCHEMBL6445033 0.77 ADORA1 (0.69) ADORA1ADORA2AADORA2BMEN1ALDH1A1
SCHEMBL6442467 0.77 ADORA1 (0.69) ADORA1ADORA2AADORA2BALDH1A1LMNA
SCHEMBL5039809 0.76 ADORA2A (0.58) ADORA1ADORA2AADORA2BMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA1 3/4885ADORA2A 1/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.